Claims for Patent: 6,780,978

Summary for Patent: 6,780,978

Title:	Fluorescence-activating antisera and IgG fraction therefrom
Abstract:	This invention allows the fluorescence analysis of a nonfluorescent dye with high specificity and high sensitivity by virtue of the formation of a complex among an antibody directed against an immunogen having the nonfluorescent dye, an antiserum containing the antibody, and the nonfluorescent dye, which is an IgG fraction of the antibody, as well as, of the manifestation of fluorescent ability of the dye, which would otherwise be nonfluorscent, resulting from the formation of the complex. Also, the invention enables higher sensitivity in fluorescence measurement where the background fluorescence is less, by employing Malachite Green which will turn into a fluorescent dye.
Inventor(s):	Jibu; Masaki (Hamamatsu, JP)
Assignee:	Hamamatsu Photonics, K.K. (Shizuoka-ken, JP)
Application Number:	10/151,437
Patent Claims:	1. An antiserum comprising an antibody directed against an antigen formed by conjugation of an immunogenic substance with a dye selected from the group consisting of dyes each having a triphenylmethane moiety and dyes each having a diphenylmethane moiety; wherein the dye is nonfluorescent when said antibody and said dye are in non-complexed form, and is fluorescent upon complexation of said antibody with said dye. 2. The antiserum according to claim 1, wherein the immunogenic substance is at least one member selected from the group consisting of bovine serum albumin, human serum albumin, egg albumin, bovine .gamma. globulin, equine serum globulin, human .gamma. globulin, ovine .gamma. globulin, bovine thyroglobulin, porcine thyroglobulin and hemocyanin. 3. The antiserum according to claim 1, wherein a fluorescence quantum yield of the dye when said dye is fluorescent is more than 100 times as large as that of the dye when said dye is nonfluorescent. 4. The antiserum according to claim 1, wherein the dye is Auramine O. 5. An IgG fraction of an antiserum comprising an antibody directed against an antigen formed by conjugation of an immunogenic substance with a dye selected from the group consisting of dyes each having a triphenylmethane moiety and dyes each having a diphenylmethane moiety; wherein the dye is nonfluorescent when said antibody and said dye are in non-complexed form, and is fluorescent upon complexation of said antibody with said dye. 6. The IgG fraction according to claim 5, wherein the immunogenic substance is at least one member selected from the group consisting of bovine serum albumin, human serum albumin, egg albumin, bovine .gamma. globulin, equine serum globulin, human .gamma. globulin, ovine .gamma. globulin, bovine thyroglobulin, porcine thyroglobuline and hemocyanin. 7. The IgG fraction according to claim 5, wherein a fluorescence quantum yield of the dye when said dye is fluorescent is more than 100 times as large as that of the dye when said dye is nonfluorescent. 8. The IgG fraction according to claim 5, wherein the dye is Auramine O. 9. A composition comprising an antibody directed against an antigen formed by conjugation of an immunogenic substance with a dye selected from the group consisting of dyes each having a triphenylmethane moiety and dyes each having a diphenylmethane moiety; wherein the dye is nonfluorescent when said antibody and said dye are in non-complexed form, and is fluorescent upon complexation of said antibody with said dye. 10. The composition according to claim 7, wherein the immunogenic substance is at least one member selected from the group consisting of bovine serum albumin, human serum albumin, egg albumin, bovine .gamma. globulin, equine serum globulin, human .gamma. globulin, ovine .gamma. globulin, bovine thyroglobulin, porcine thyroglobulin and hemocyanin. 11. The composition according to claim 7, wherein a fluorescence quantum yield of the dye when said dye is fluorescent is more than 100 times as large as that of the dye when said dye is nonfluorescent. 12. The composition according to claim 7, wherein the dye is Auramine O.

Details for Patent 6,780,978

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2018-01-07
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2018-01-07
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2018-01-07
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2018-01-07
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2018-01-07